Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T04:51:16.256Z Has data issue: false hasContentIssue false

25 - Prospects

Published online by Cambridge University Press:  27 August 2009

Mark A. Feitelson
Affiliation:
Thomas Jefferson University, Philadelphia
Get access

Summary

The “silent” epidemic of hepatitis C is no longer silent, thanks to the discovery and molecular cloning of the virus, coupled with the development and deployment of assays that specifically detect anti-HCV and HCV RNA in infected patients. These combined approaches have reduced the risk of acquiring HCV from contaminated blood to almost zero. On the clinical level, the challenge is to try to stem the magnitude of the epidemic in the foreseeable future by intensifying community outreach and education programs designed to avoid infection: making the public aware of the remaining major risk factors, including IV drug abuse and the problems of transmission associated with multiple sexual partners. For those already infected, the need for counseling has never been greater, not only for the prevention of transmission but also in making important therapeutic decisions that patients can live with. Fortunately, the use of IFN and ribavirin combination therapy has provided a great deal of hope for chronically infected patients, who otherwise have a very high risk for the development of end-stage liver disease. There is still a long way to go before all patients with chronic HCV infection can be effectively and safely treated. The combination of high throughput screening assays (using individual virus gene products produced by recombinant DNA technology), and the willingness of physicians to introduce some of the best candidates into clinical trials, will invariably lead to an improvement in the therapeutic tools available and the outcome of infection.

Type
Chapter
Information
Hepatitis C Virus
From Laboratory to Clinic
, pp. 175 - 176
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Prospects
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.027
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Prospects
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.027
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Prospects
  • Mark A. Feitelson, Thomas Jefferson University, Philadelphia
  • Book: Hepatitis C Virus
  • Online publication: 27 August 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545320.027
Available formats
×